JP2019523759A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019523759A5 JP2019523759A5 JP2018562123A JP2018562123A JP2019523759A5 JP 2019523759 A5 JP2019523759 A5 JP 2019523759A5 JP 2018562123 A JP2018562123 A JP 2018562123A JP 2018562123 A JP2018562123 A JP 2018562123A JP 2019523759 A5 JP2019523759 A5 JP 2019523759A5
- Authority
- JP
- Japan
- Prior art keywords
- pad4
- patient
- assay
- antigen
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023008716A JP2023058524A (ja) | 2016-05-24 | 2023-01-24 | 関節リウマチの治療のための臨床応答バイオマーカーとしての抗ｐａｄ４自己抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662340560P | 2016-05-24 | 2016-05-24 | |
| US62/340,560 | 2016-05-24 | ||
| PCT/EP2017/062479 WO2017202879A1 (en) | 2016-05-24 | 2017-05-23 | Anti-pad4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023008716A Division JP2023058524A (ja) | 2016-05-24 | 2023-01-24 | 関節リウマチの治療のための臨床応答バイオマーカーとしての抗ｐａｄ４自己抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019523759A JP2019523759A (ja) | 2019-08-29 |
| JP2019523759A5 true JP2019523759A5 (https=) | 2020-07-02 |
| JP7217631B2 JP7217631B2 (ja) | 2023-02-03 |
Family
ID=59009670
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018562123A Active JP7217631B2 (ja) | 2016-05-24 | 2017-05-23 | 関節リウマチの治療のための臨床応答バイオマーカーとしての抗ｐａｄ４自己抗体 |
| JP2023008716A Ceased JP2023058524A (ja) | 2016-05-24 | 2023-01-24 | 関節リウマチの治療のための臨床応答バイオマーカーとしての抗ｐａｄ４自己抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023008716A Ceased JP2023058524A (ja) | 2016-05-24 | 2023-01-24 | 関節リウマチの治療のための臨床応答バイオマーカーとしての抗ｐａｄ４自己抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11613580B2 (https=) |
| EP (1) | EP3464358A1 (https=) |
| JP (2) | JP7217631B2 (https=) |
| AU (1) | AU2017270027B2 (https=) |
| CA (1) | CA3024910A1 (https=) |
| MA (1) | MA45112A (https=) |
| WO (1) | WO2017202879A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017270027B2 (en) * | 2016-05-24 | 2024-07-11 | Medimmune Limited | Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis |
| CA3129624A1 (en) * | 2019-02-15 | 2020-08-20 | Inova Diagnostics, Inc. | Compositions and methods for diagnosing and assessing rheumatoid arthritis |
| US20210284744A1 (en) | 2020-03-15 | 2021-09-16 | Kiniksa Pharmaceuticals, Ltd. | Treatment of cytokine release syndrome with gm-csf antagonists |
| CN111458522B (zh) * | 2020-04-20 | 2024-01-09 | 杭州英邈生物科技有限公司 | 一种用于检测血浆白细胞介素6天然抗体的检测试剂、试剂盒及其应用 |
| CN111733151B (zh) * | 2020-07-13 | 2021-11-12 | 山东新创生物科技有限公司 | 一种基于padi4作为肿瘤标志物制得的抗原、抗体及应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US6818406B2 (en) | 2001-03-23 | 2004-11-16 | Mayo Foundation For Medical Education And Research | Rheumatoid arthritis markers |
| CA2525179A1 (en) | 2003-05-08 | 2004-12-23 | Vanderbilt University | A gene equation to diagnose rheumatoid arthritis |
| PL1999152T3 (pl) | 2006-03-27 | 2013-05-31 | Medimmune Ltd | Element wiążący receptor GM-CSF |
| JP5252339B2 (ja) | 2007-12-25 | 2013-07-31 | 地方独立行政法人東京都健康長寿医療センター | Ｐａｄ４及び抗ｐａｄ４抗体の測定方法並びに関節リウマチの検出方法 |
| AU2010233926B2 (en) * | 2009-03-30 | 2014-01-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Biomarkers, methods and kits for the diagnosis of Rheumatoid Arthritis |
| WO2011066372A2 (en) | 2009-11-25 | 2011-06-03 | The Johns Hopkins University | Citrullination of human peptidylarginine deiminase 4 (pad-4) regulates its function and immunogenicity |
| EP2766394B1 (en) | 2011-10-10 | 2017-11-22 | Medimmune Limited | Treatment for rheumatoid arthritis |
| US8975033B2 (en) | 2012-11-05 | 2015-03-10 | The Johns Hopkins University | Human autoantibodies specific for PAD3 which are cross-reactive with PAD4 and their use in the diagnosis and treatment of rheumatoid arthritis and related diseases |
| EP3145541A1 (en) | 2014-05-19 | 2017-03-29 | Medimmune Limited | Treatment for rheumatoid arthritis |
| AU2017270027B2 (en) * | 2016-05-24 | 2024-07-11 | Medimmune Limited | Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis |
-
2017
- 2017-05-23 AU AU2017270027A patent/AU2017270027B2/en active Active
- 2017-05-23 WO PCT/EP2017/062479 patent/WO2017202879A1/en not_active Ceased
- 2017-05-23 EP EP17727829.8A patent/EP3464358A1/en active Pending
- 2017-05-23 MA MA045112A patent/MA45112A/fr unknown
- 2017-05-23 CA CA3024910A patent/CA3024910A1/en active Pending
- 2017-05-23 JP JP2018562123A patent/JP7217631B2/ja active Active
- 2017-05-23 US US16/304,055 patent/US11613580B2/en active Active
-
2023
- 2023-01-24 JP JP2023008716A patent/JP2023058524A/ja not_active Ceased
- 2023-02-14 US US18/169,205 patent/US20230303707A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019523759A5 (https=) | ||
| Ha et al. | Usefulness of serum leucine-rich alpha-2 glycoprotein as a disease activity biomarker in patients with rheumatoid arthritis | |
| RU2013106938A (ru) | Биомаркеры в плазме крови, предназначенные для комбинированных терапий с использованием бевацизумаба при лечении рака молочной железы | |
| CN107110853A (zh) | 确定TNFα抑制药及其相应抗药抗体的量的通用测定法 | |
| WO2015034926A1 (en) | Treatment methods for rheumatoid arthritis | |
| Sandborn et al. | Effects of transient and persistent anti-drug antibodies to certolizumab pegol: longitudinal data from a 7-year study in Crohn's disease | |
| JP2023058524A (ja) | 関節リウマチの治療のための臨床応答バイオマーカーとしての抗ｐａｄ４自己抗体 | |
| JP2021507236A (ja) | プロカルシトニンと中間領域プロアドレノメデュリンを使用したリスク評価と患者管理のためのワークフロー | |
| Vlam et al. | Association of IgM monoclonal gammopathy with progressive muscular atrophy and multifocal motor neuropathy: a case–control study | |
| RU2016135417A (ru) | Новый анализ для детектирования периостина человека | |
| Uojima et al. | Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: a randomized study | |
| Ebach et al. | High body mass index and response to anti-tumor necrosis factor therapy in pediatric crohn’s disease | |
| Kamounah et al. | Immunoassay detects salivary anti-SSA/Ro-52 autoantibodies in seronegative patients with primary Sjögren’s syndrome | |
| Eric et al. | Interleukin 33, soluble suppression of tumorigenicity 2, interleukin 27, and galectin 3 as predictors for outcome in patients admitted to intensive care units | |
| JP2013511730A (ja) | 血小板バイオマーカーの正規化方法 | |
| Chavarria-Avila et al. | Going further: Comprehensive disease control of rheumatoid arthritis, targeting cytokines and chemokines | |
| Kim et al. | Albumin-to-Globulin Ratio at 1 Year after Anti-Tumor Necrosis Factor α Therapy Can Serve as a Prognostic Biomarker in Pediatric Crohn’s Disease Patients | |
| Sammut et al. | Albuminuria in rheumatoid arthritis: associations with rheumatoid arthritis characteristics and subclinical atherosclerosis | |
| Minawala et al. | Sarcopenia as a preoperative risk stratification tool among older adults with inflammatory bowel disease | |
| EP4558825A1 (en) | Meteorin-like protein (metrnl) as (blood) biomarker for the diagnosis of polycystic ovarian syndrome | |
| BR112020004138A2 (pt) | pro-adm como marcador de monitoramento terapêutico para pacientes doentes em estado crítico | |
| CN103180731B (zh) | 纤维肌痛症的诊断剂、诊断方法及治疗剂 | |
| Matthies et al. | Enhancing the Affinity of a Novel Selective scFv for Soluble ST2 through Computational Design | |
| Doi et al. | Neutrophil CD64 expression as a diagnostic marker for local infection and crystal-induced arthritis | |
| Faghy et al. | Current status and future perspectives on the mechanistic and pathophysiological understanding of long COVID |